Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab

Annals of Pharmacotherapy

Volumn 49, Issue 12, 2015, Pages 1327-1335

  White, C Michael ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

alirocumab; evolocumab; familial hypercholesterolemia; hypercholesterolemia; PCSK9 inhibitors

Indexed keywords

ALIROCUMAB; CREATINE KINASE; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

AUTOSOMAL DOMINANT INHERITANCE; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; BLOOD; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOLOGY; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84947257952     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015608487     Document Type: Review

References (38)

1. C.M.White. MTM essentials for cholesterol management. Drug Topics. 2014;2:64-73.
2. Repatha [package insert and label information]. http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf. Accessed September 2, 2015.
3. Praluent [package insert and label information]. http://druginserts.com/lib/rx/meds/praluent/. Updated July24, 2015. Accessed August 12, 2015.
4. IAD Week. Regeneron, Sanofi price Praluent at $14,560/Yr: market talk. http://iadweek.me/2015/07/24/regeneron-sanofi-price-praluent-at-14560yr-market-talk/. Accessed August 12, 2015.
5. M.O’Riordan. Enthusiasm for PCSK9 inhibitors remains high but guarded before FDA advisory panels. http://www.medscape.com/viewarticle/845929_print. Accessed July 2, 2015.
6. B.P.FalitS.C.SinghT.A.Brennan. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. Health Aff (Millwood). 2015;34:1-8.
7. N.J.StoneJ.RobinsonA.H.Lichtenstein; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25, suppl 2):S1-S45. doi:10.1161/01.cir.0000437738.63853.7a.
8. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
9. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
10. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212.
11. P.J.BarterM.CaulfieldM.Eriksson. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
12. C.P.CannonM.A.BlazingR.P.Guigliano. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
13. C.P.CannonE.BraunwaldC.H.McCabe. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
14. J.C.LaRosaS.M.GrundyD.D.Waters. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
15. P.M.RidkerE.DanielsonF.A.Fonseca. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
16. J.G.RobinsonA.C.Goldberg. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:s18-s29.
17. A.NeilJ.CooperJ.Betteridge. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study. Eur Heart J. 2008;29:2625-2633.
18. C.StefanuttiU.Julius. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19-27.
19. A.D.SnidermanS.TsimikasS.Fazio. The severe hypercholesterolemia phenotype. J Am Coll Cardiol. 2014;63:1935-1947.
20. T.B.RepasJ.R.Tanner. Preventing early cardiovascular death in patients with familial hypercholesterolemia. J Am Osteopath Assoc. 2014;114:99-108.
21. G.D.NorataG.TibollaA.L.Catapano. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vasc Pharmacol. 2014;62:103-111.
22. A.F.CiceroE.TartagniS.Ertek. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Exp Opin Drug Saf. 2014;13:1023-1030.
23. D.J.RaderJ.CohenH.H.Hobbs. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795-1803.
24. H.H.HobbsM.S.BrownJ.L.Goldstein. Molecular genetics of the LDLR gene in familial hypercholesterolemia. Hum Mutat. 1992;1:445-466.
25. G.F.WattsS.GiddingA.S.Wierzbicki. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Int J Cardiol. 2014;171:309-325.
26. M.Farnier. PCSK9 inhibitors. Curr Opin Lipidol. 2013;24:251-258.
27. T.P.Leren. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65:419-422.
28. M.BennB.G.NordestgaardP.Grande. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analysis. J Am Coll Cardiol. 2010;55:2833-2842.
29. J.C.CohenE.BoerwinkleT.H.MosleyH.H.Hobbs. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
30. Cancerology. Evolocumab approved in Europe. http://cancerology.blogspot.com/2015/07/evolocumab-approved-in-europe.html. Accessed August 12, 2015.
31. E.P.NavareseM.KolodziejczakV.Schulze. Effects of proprotein convertase subtilisin/Kexin type 9 antibodies in adults with hypercholesterolemia. Ann Intern Med. 2015;163:40-51.
32. C.LiL.LinW.Zhang. Efficacy and safety of proprotein convertase substilsin/Kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc. 2015;4:e001937.
33. F.J.RaalN.HonarpourD.J.Blom. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomized, double-blind, placebo-controlled trial. Lancet. 2015;385:341-350.
34. R.T.DaduC.M.Ballentyne. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11:563-575.
35. Meta-Analysis.com. Fixed-Effect Versus Random-Effects Models. Englewood, NJ: Biostat; 2009. http://www.meta-analysis.com/downloads/Intro_Models.pdf. Accessed July 17, 2015.
36. J.G.RobinsonM.FarnierM.Krempf; for the ODYSSEY Long Term Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.
37. M.A.SabatineR.P.GiuglianoS.D.Wiviott. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509.
38. X.L.ZhangQ.Q.ZhuL.Zhu. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. doi:10.1186/s12916-015-0358-8.